Related Experiment Video
Updated: Aug 9, 2026

Optimization, Test and Diagnostics of Miniaturized Hall Thrusters
Published on: February 16, 2019
A short report on highlights of worldwide development of RIX4414: a Singaporean experience
K B Phua1, S H Quak, S Emmanuel
1Department of Pediatrics, KK Women's and Children's Hospital, 100 Bukit Timah Road, Singapore 229899, Singapore. kbphua@kkh.com.sg
Insights
This study found that the RIX4414 rotavirus vaccine was safe and effective in Singaporean infants. High rates of seroconversion and
Area of Science:
- Pediatric infectious diseases
- Vaccinology
- Immunology
Background:
- Rotavirus is a leading cause of severe diarrheal disease in infants globally.
- Effective rotavirus vaccines are crucial for public health interventions.
- Previous studies have explored various rotavirus vaccine candidates.
Purpose of the Study:
- To evaluate the safety and immunogenicity of an attenuated human rotavirus vaccine (RIX4414) in a dose-ranging study.
- To determine the optimal dose of RIX4414 for infants in Singapore.
- To assess the vaccine's tolerability and interference with routine immunizations.
Main Methods:
- Phase II, randomized, double-blind, placebo-controlled, dose-ranging study.
- 2464 healthy infants received two oral doses of RIX4414 (three dose levels) or placebo.
- Vaccinations were administered at 3 and 4 months of age alongside routine immunizations.
- Seroconversion and 'vaccine take' were assessed 1 month post-dose 2.
Main Results:
- Seroconversion rates ranged from 76% to 91% across vaccine groups.
- 'Vaccine take' was observed in 98% to 100% of vaccine recipients.
- The vaccine was well tolerated with no significant adverse events reported.
- Concomitant administration with routine vaccines did not affect immune responses.
Conclusions:
- Attenuated human rotavirus vaccine RIX4414 demonstrated favorable safety and immunogenicity in Singaporean infants.
- The vaccine achieved high seroconversion and 'vaccine take' rates.
- RIX4414 can be safely co-administered with routine infant immunizations.
Abstract:
In Singapore, we conducted a phase II randomized, double-blind, placebo-controlled dose ranging study using an attenuated human rotavirus vaccine, RIX4414. Altogether, 2464 healthy infants were recruited. Two oral doses of vaccine at 104.7, 105.2 or 106.1 ffu or placebo were administered with routine immunizations at 3 and 4 months of age. Seroconversion and 'vaccine take' in the vaccine groups 1-month post dose 2 varied from 76 to 91% and 98 to 100% respectively. Vaccine was well tolerated and did not interfere with response of concomitantly administered vaccines.
Related Concept Videos
Design Example
Semiconductors
Metals such as copper (Cu), zinc (Zn), or lead (Pb) have low resistivity and feature conduction bands that are either not fully occupied or overlap with the valence band, making a bandgap non-existent. This allows electrons in the highest energy levels of the valence band to easily transition to the conduction band upon gaining...
Clipper Circuit
The operation of a clipper circuit can be exemplified by analyzing a dual-clipper configuration setup that integrates two ideal diodes, each paired with a biasing...
Design Example: Vintage Mixing Console
The specifications for the pre-amplifier were clear. It needed to amplify the audio signal by a factor of 10, have an input impedance above 10...
Electro-mechanical Systems
A key component of the DC motor is the armature, a rotating circuit positioned within a magnetic field. As an electric current passes through the...
iChip

